Main-Banner-v3B-01.jpg
Banners-05.png
Banners-07.png
Banners-06.png
Banners-08.png
Banners-05.png
Banners-07.png
Banners-06.png
Banners-05.png

Focus


Focus


Goldfinch is singularly focused on discovering and developing precision therapies for patients with kidney disease.

Chronic kidney disease is a driver of mortality across age, race, and stage of disease progression, affecting over 1 in 9 people worldwide. It has emerged as a global epidemic and growing problem that places an enormous social and economic burden on patients, their families, and society.

Advances in kidney transplantation and dialysis over half a century ago extended life for patients with kidney failure, yet the current standard of care for patients with kidney disease remains inadequate, and there is an urgent need for new treatment options.

Recent breakthroughs in genetics and biology have generated an unparalleled understanding of the biological pathways that drive kidney disease. Goldfinch is uniquely positioned to translate these discoveries into new therapies that target the molecular causes of kidney disease.

 

The burden of kidney disease for patients and society

Banners-07.png

team


team


Goldfinch brings together experts in the field and experienced leaders with a shared mission to pioneer new treatments for patients with kidney disease.

LEADERSHIP

Abbie Celniker, Ph.D

Interim CEO

Abbie Celniker, Ph.D.

Interim CEO

Abbie Celniker is a partner at Third Rock Ventures, and brings 30 years of experience in R&D and senior leadership roles. Abbie focuses on the formation, development and strategy of Third Rock's portfolio companies.

Prior to joining Third Rock Ventures, she served as president and CEO of Eleven Biotherapeutics since 2011. Previously, Abbie was the president and CEO of Taligen Therapeutics from 2008 to 2011, when Taligen Therapeutics was acquired by Alexion Pharmaceuticals; following the acquisition, she served as Alexion's executive vice president, translational medicine. She has served as the global head of biologics of Novartis AG, the senior vice president of R&D strategy and operations of Millennium Pharmaceuticals, Inc. and the vice president of protein technologies of the Wyeth Research facilities.

Abbie is the chair of MassBio's board of directors, a member of the board of ImaginAb, where she was previously the chair, and a member of the scientific advisory board for Adimab. She is also a member of the board of directors of the nonprofit Unitio and T1D. She has a B.A. in Biology from the University of California, San Diego, and a Ph.D. in Molecular Biology from the University of Arizona.

Neil Exter

Interim COO

Neil Exter

Interim COO

Neil Exter is a partner at Third Rock Ventures, which he joined in 2007. Neil has more than 20 years of business development and strategic experience facilitating the successful development and implementation of operations and collaborations across the spectrum of newly emerging and established biotechnology companies. He plays an integral role in the formation, development and business strategy for portfolio companies.

Prior to joining Third Rock, Neil was chief business officer of Alantos Pharmaceuticals, leading the sale of the company to Amgen, and earlier, served as vice president for Millennium Pharmaceuticals, directing in-licensing and M&A. Earlier in his career, Neil held various executive and senior management roles within the high technology industry, including tenures at Hewlett Packard and Wang Laboratories.

Neil holds an MBA as a Baker Scholar from Harvard Business School, an M.S. from Stanford University and a B.S. from Cornell University. He is a member of the Research Committee of Children's Hospital Boston, a member of the investment committee of the Innovation Research Fund and Innovation Advisory Board at Partners Healthcare and the treasurer and a member of the board of directors of the New England Venture Capital Association. In addition, Neil serves as a member of the Advisory Council of the Electrical and Computer Engineering Department at Cornell University and the board of visitors of Columbia College.

Phil Reilly, M.D., J.D.

Interim CMO

Phil Reilly is a Venture Partner at Third Rock Ventures, which he joined in 2008 to discover, launch and build companies pursuing breakthrough treatments for rare genetic diseases. He is a highly respected clinical geneticist with an extensive track record of launching and building companies in the rare disease space.

In addition to his role at Third Rock, Phil is a trustee emeritus of Cornell University, is an Overseer of Weill Cornell Medical College, and serves on the Advisory Board to the Boston University School of Public Health. Prior to joining Third Rock, he was the chief executive officer and chairman of Interleukin Genetics, and before that, he was the executive director of the Eunice Kennedy Shriver Center for Mental Retardation. He served twice (2000 and 2003) as president of the American Society of Law, Medicine and Ethics. He is a founding fellow of the American College of Medical Genetics. He has authored or co-authored more than 100 articles in scholarly journals and has published seven books including most recently Orphan: The Quest to Save Children with Rare Genetic Disorders. Phil has held teaching positions at Tufts University School of Medicine and Harvard Medical School. He received his B.A. from Cornell University and holds an M.D. from Yale University, a J.D. from Columbia University, is a member of the Massachusetts Bar and is board certified in internal medicine and clinical genetics.

Jean-Christophe Harmange, Ph.D.

Senior Vice President of Drug Discovery

Jean-Christophe Harmange, Ph.D.

Senior Vice President of Drug Discovery

Jean-Christophe Harmange joined Goldfinch Bio after serving as Entrepreneur-In-Residence at Third Rock Ventures, where he played a leading role in launching Goldfinch Bio. Jean-Christophe brings more than 20 years of drug discovery, preclinical and early clinical development experience in large and small biopharmaceutical companies. He has led multidisciplinary discovery teams and research and development organizations in delivering several clinical development candidates. Jean-Christophe is co-inventor on more than 30 issued U.S. patents and the author of numerous publications.

Prior to his tenure at Third Rock Ventures, he served as the executive director of drug discovery at Constellation Pharmaceuticals where he was integral in building one of the premier epigenetic drug discovery organizations. He also held positions of increasing responsibility at Amgen, Eisai and Servier. Jean-Christophe received his Pharm.D. and Ph.D. in organic chemistry from the Université Paris-Sud and completed his postdoctoral training at Harvard University in Professor Yosito Kishi's laboratory.

Peter Mundel, M.D.

Senior Vice President of Biology

Peter Mundel, M.D.

Senior Vice President of Biology

Peter Mundel joined Goldfinch Bio after serving as a Consultant to Third Rock Ventures, where he played a leading role in the creation and launch of Goldfinch Bio. Peter brings more than 25 years of experience as a leader in academic research, most recently at Massachusetts General Hospital and Harvard Medical School. A major focus of Peter's work has been the development of precision therapeutics for patients with kidney diseases through a mechanistic understanding of the cell biology and pathology of the kidney, with a focus on podocytes. A pioneer of molecularly targeted treatment for proteinuric kidney disease, Peter has published more than 140 peer-reviewed manuscripts and has given numerous invited lectures nationally and internationally. He is a member of the American Society for Clinical Investigation.

As a recognized leader in the field of nephrology, Peter is the recipient of many awards including the Young Investigator Award from the American Society of Nephrology and the American Heart Association. Peter holds an M.D. from the University of Heidelberg, Germany.

Thomas Tibbitts, Ph.D.

Vice President of Computational Discovery

Thomas Tibbitts, Ph.D.

Vice President of Computational Discovery

Thomas Tibbitts comes to Goldfinch Bio from an immuno-oncology pharma company where he spent 11 years contributing to a wide range of drug discovery projects, leading structure-guided drug design as a co-inventor on a number of patents for small molecule therapeutics, two of which are currently in clinical development. As the genomics revolution took hold, he built out computational translational genomics to support clinical trials, and helped drive preclinical studies using transcriptomics to elucidate the mechanism of drug action in the tumor microenvironment and provide a basis for rational I/O drug combinations. He brings expertise in genomics, transcriptomics, informatics, software development, image analysis, protein crystallography and cloud computing. As leader of the patient registry at Goldfinch, he is passionate about leveraging his eclectic skill set and experience in genomics to bring new precision medicines to patients suffering from chronic kidney disease. Thomas holds a Ph.D. in Biophysics and has co-authored recent papers in major journals including Nature and J. Medicinal Chemistry.

Thomas Martz

Director of Corporate Development

Thomas Martz

Director of Corporate Development

Thomas Martz joined Goldfinch Bio after serving as a Senior Associate at Third Rock Ventures, where he played a leading role in the formation and launch of Goldfinch. Thomas joined Third Rock in 2015 to focus on new company creation and due diligence.

Prior to Third Rock, Thomas obtained his MBA from the MIT Sloan School of Management, where he interned in multiple strategic and business development roles at biotechnology companies including Alnylam Pharmaceuticals, Editas Medicine and Eleven Biotherapeutics. Previously, Thomas was a senior consultant in Deloitte's Life Sciences practice, where he worked with life sciences organizations and stakeholders in scientific and technological areas spanning R&D strategy and commercial operations. Before Deloitte, Thomas worked in multiple roles of increasing responsibility across biopharmaceutical research at Novartis and Biogen. In addition to his MBA, Thomas holds a B.S. in biochemistry from Boston College.





Founders and advisors

Our Founders and Advisors are world-renowned scientists and clinicians at the forefront of kidney biology, genetics, and genomics.

Joseph Bonventre, M.D., Ph.D.

Harvard Medical School, MIT, Brigham and Women's Hospital

Joseph Bonventre, M.D., Ph.D.

Samuel A. Levin Professor of Medicine at Harvard Medical School
Professor of Health Sciences and Technology, Massachusetts Institute of Technology
Chief of the Renal Division and Founding Chief of the Engineering in Medicine Division, Brigham and Women's Hospital

Joseph Bonventre's research focuses primarily on the study of kidney injury and repair and signal transduction, with a special emphasis on the role of inflammation, biomarkers and stem cells. He has more than 350 original research publications, 150 reviews/chapters and editorials and 3 books. His recent work also involves the generation of kidney organoids from stem cells and their use in kidney disease modeling. He has been elected to the American Society of Clinical Investigation (ASCI), the Association of American Physicians (AAP), the American Clinical and Climatological Association (ACCA) and the American Institute for Medical and Biological Engineering (AMBIE). He is a member of the Executive Committee of the Harvard Stem Cell Institute (HSCI).

Joseph is past-president of the American Society of Nephrology and founding member of the Board of Directors of the National Space Biology Research Institute. Joseph has chaired and served on many NIH Study Sections and is Editor of Seminars in Nephrology. He has been awarded the Osler Medal of the Royal Society of Physicians and the Bywaters Award of the International Society of Nephrology. He currently serves as a member of the NIH National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Advisory Council.

In addition to his B.S. with distinction in Engineering Physics from Cornell, Joseph holds M.D. and Ph.D. degrees in biophysics from Harvard University. He has honorary doctorate degrees from Mt. Saint Mary's College and from the Norwegian Institute of Science and Technology in Norway. He was Director of the Harvard-MIT Division of Health Sciences and Technology for 10 years.

Anna Greka, M.D., Ph.D.

The Broad Institute, Harvard Medical School, Brigham and Women’s Hospital

Anna Greka, M.D., Ph.D.

Assistant Professor at Harvard Medical School
Institute Member at the Broad Institute of MIT and Harvard
Founding Director of Glom-NExT Center for Glomerular Kidney Disease and Novel Experimental Therapeutics

Anna Greka leads an interdisciplinary team of students, postdoctoral fellows and staff scientists in laboratories at Brigham and Women’s Hospital, Harvard Medical School and the Broad Institute working on diverse projects spanning ion channel biophysics, pharmacology, cell biology, biochemistry, imaging, in vivo studies and computational biology.

Anna currently serves as the founding director of Glom-NExT, a center focused on the development of novel experimental therapeutics at Brigham and Women's Hospital and Harvard Medical School. In addition to teaching at Harvard Medical School, she serves on the Harvard-MIT MD-PhD Leadership Council.

Anna has given numerous invited lectures nationally and internationally, and she is the recipient of several honors including a career development award from the American Society of Nephrology, a 2014 Top10 Award from the Clinical Research Council, and a 2014 Young Physician Scientist Award from the American Society of Clinical Investigation.

Anna holds an A.B. from Harvard College and an MD and PhD from Harvard Medical School and the Harvard-MIT M.D.-Ph.D. program in the Division of Health Sciences and Technology (HST). She completed her graduate work in the laboratory of David Clapham in work funded by a Howard Hughes Medical Institute (HHMI) Fellowship.

Friedhelm Hildebrandt, M.D.

Harvard Medical School, Boston Children's Hospital

Friedhelm Hildebrandt, M.D.

Warren E. Grupe Professor of Pediatrics at Harvard Medical School
Chief of the Division of Nephrology of Boston Children's Hospital

Friedhelm Hildebrandt's research work is concerned with the identification and functional characterization of recessive single-gene causes of kidney diseases in children and young adults, including nephrotic syndrome, cystic renal ciliopathies, and congenital anomalies of the kidney. His group has identified over 80 novel monogenic causative genes for chronic kidney disease and delineated the related pathogeneses.

Friedhelm has published over 280 original articles in high-ranking journals. He has received the Mead Johnson Award by the Pediatric Academic Societies, the Homer W. Smith Award by the American Society of Nephrology (ASN), the Lillian Jean Kaplan Award for PKD Research, and the Franz Volhard Award. He is a member of the American Association of Physicians (AAP), the German National Academy of Sciences, and the National Academy of Medicine (NAS/IOM), and is an alumnus investigator of the Howard Hughes Medical Institute (HHMI).

Daniel MacArthur, Ph.D.

The Broad Institute, Harvard Medical School, Massachusetts General Hospital

Daniel MacArthur, Ph.D.

Co-Director of the Medical and Population Genetics Program at the Broad Institute of MIT and Harvard
Assistant Professor at Harvard Medical School and Massachusetts General Hospital

Daniel MacArthur is a geneticist with a long-standing focus on the use of large-scale genomic data sets to improve the interpretation of human genetic variation, with a special focus on rare disease diagnosis. He led the formation of the Exome Aggregation Consortium (ExAC), a collection of sequence data from over 60,000 people, which has become a critical resource in clinical genetics. He also co-directs the Broad Institute's Center for Mendelian Genomics, and has led the sequencing of over 3,000 members of families affected by rare disease. He has over 15 years of experience in human genetics, including a Ph.D. from the University of Sydney, Australia, and postdoctoral training in genomics at the Wellcome Trust Sanger Institute in Cambridge, UK.

Peter Mundel, M.D.

Goldfinch Bio

Peter Mundel, M.D.

Senior Vice President of Biology, Goldfinch Bio

Peter Mundel joined Goldfinch Bio after serving as a Consultant to Third Rock Ventures, where he played a leading role in the creation and launch of Goldfinch Bio. Peter brings more than 25 years of experience as a leader in academic research, most recently at Massachusetts General Hospital and Harvard Medical School. A major focus of Peter's work has been the development of precision therapeutics for patients with kidney diseases through a mechanistic understanding of the cell biology and pathology of the kidney, with a focus on podocytes. A pioneer of molecularly targeted treatment for proteinuric kidney disease, Peter has published more than 140 peer-reviewed manuscripts and has given numerous invited lectures nationally and internationally. He is a member of the American Society for Clinical Investigation.

As a recognized leader in the field of nephrology, Peter is the recipient of many awards including the Young Investigator Award from the American Society of Nephrology and the American Heart Association. Peter holds an M.D. from the University of Heidelberg, Germany.

Stefan Somlo, M.D.

Yale School of Medicine

Stefan Somlo, M.D.

C. N. H. Long Professor of Medicine, Professor of Genetics, and Chief of the Section of Nephrology at the Yale School of Medicine

Steve Somlo's research interest over the past 25 years has been to understand the genetic and biological bases of human polycystic kidney and liver diseases. His laboratory began with discovering disease genes for autosomal dominant polycystic kidney disease (PKD2), isolated polycystic liver disease (PRKCSH, SEC63) and recessive polycystic kidney disease (PKHD1). His group used these discoveries as the starting point from which to define both genetic and cellular mechanisms underlying the respective human diseases.

Steve graduated from Harvard College and the College of Physicians and Surgeons of Columbia University. He did his clinical training at the Albert Einstein College of Medicine and Yale and was on faculty at Albert Einstein before returning to Yale. He is a member of the American Society for Clinical Investigation and Association of American Physicians and is a recipient of the Lillian Jean Kaplan International Prize for Polycystic Kidney Disease Research and the Homer W. Smith Award from the American Society of Nephrology.

Banners-06.png

Approach


Approach


Goldfinch is integrating breakthroughs in kidney genetics and biology to identify new therapeutic targets and advance first-in-class drug candidates to treat patients with kidney disease.

 
 

Goldfinch’s Product Engine will industrialize the integration of genetics and kidney biology and confer a differentiated ability to identify, validate, and pursue novel therapeutic targets for kidney disease.

Banners-08.png

Programs


Programs


Goldfinch’s therapeutic programs are underscored by strong genetic validation and a deep familiarity of the biological pathways that cause disease. Our initial efforts are focused on focal segmental glomerulosclerosis (FSGS) and polycystic kidney disease (PKD).


FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)

Programs-02-v2-01.png

Focal Segmental Glomerulosclerosis (FSGS), a rare kidney disorder, is a histopathologic diagnosis characterized by severe scarring of the kidney's filtering units, or glomeruli, leading to an excess of essential proteins spilling into the urine, called proteinuria. FSGS is a leading cause of kidney failure, and patients with diagnosed FSGS are at increased risk of heart attack, stroke and premature death.

There are currently no FDA approved treatments for FSGS. Existing treatments are non-specific, do not alter the progression of disease and carry significant toxicities.

Goldfinch is leading the charge to develop treatments targeting the molecular causes of FSGS to drastically improve the lives of patients suffering from this devastating, life-shortening condition.


POLYCYSTIC KIDNEY DISEASE (PKD)

Programs-02-v2-01.png

Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common single gene diseases, affecting more than 600,000 people in the US and 12 million worldwide. The disease is passed on from parent to child, with each child of an affected parent having a 1-in-2 chance of inheriting the disorder, which does not skip generations.

ADPKD patients develop fluid filled cysts in both kidneys that increase in number and size over time, culminating in end stage kidney disease in half of affected individuals by middle age. ADPKD commonly causes liver cysts which arise from bile ducts and can sometimes grow large enough to cause symptoms as well. In the United States, 1 in 20 individuals either on dialysis or with a kidney transplant has ADPKD.

There are no FDA approved therapies specifically targeting ADPKD and no means by which to alter the course of the disease.

Goldfinch is leveraging scientific discoveries based on the known genes that cause ADPKD to discover treatments to alter the course of ADPKD and drastically improve the lives of patients suffering from this chronic and debilitating disease.

Banners-05.png

Patients


Patients


It is the patients with kidney disease who will lead us to the understanding of pathways and targets that will drive transformative drug development. To accomplish this, we will partner with patients to build the world’s most comprehensive registry of individuals with molecularly defined kidney disease.

Goldfinch is assembling a database of genetic, genomic and clinical information from consented patients who have provided thousands of DNA samples and anonymized clinical records. Building off of the studies of our founders and partners, we will deeply study DNA and correlate findings with clinical data. We will then use novel computational tools to mine for evidence of the DNA variants that increase risk for kidney disease and suggest new ways to treat and prevent it.

Banners-06.png

Careers


Careers


At Goldfinch, we are pioneering a new approach to discover and develop therapeutics for kidney disease that is unprecedented.

Where others see risk, we see opportunity to make an impact and redefine the state of care for patients with kidney disease. We recognize the importance of collaboration, and strive to work alongside patients, clinicians and other partners to empower patients and develop treatments for conditions where no approved therapies exist.

We’re looking for teammates who relish the challenge, and are compelled to leave a positive mark on the lives of colleagues and patients alike.

If this sounds like the community you want to grow with, we invite you to explore our current career opportunities below.

If you would like to be considered for an opportunity at Goldfinch Bio, please submit your CV with the title of the position in the subject line to careers@goldfinchbio.com.

JOIN THE RENAISSANCE

  • Director, Lead Discovery

    The Opportunity

    The Head of Lead Discovery will be responsible for developing and implementing small molecule screening strategies, biochemical and biophysical assays, deciphering mechanism of actions and support compound management. S/he will be working closely with Goldfinch biologists and medicinal chemists to enable drug discovery from hit identification to candidate selection.

    Major Responsibilities

    • Develop, as a member of cross functional teams, screening strategies to identify genuine modulators of Goldfinch’s targets
    • Oversee implement of screens (DEL screen, HTS, MTS, fragment screen) and hit characterization
    • Develop and oversee implementation of biochemical and biophysical assays to support Goldfinch’s drug discovery, including selectivity panels
    • Design experiments and analyze data to characterize small molecule modulators enzymological/biochemical parameters
    • Outsource development and implementation of routine biochemical assays, selectivity panels and screens
    • Manage protein chemistry to support drug discovery
    • Implement stage appropriate compound management strategies
    • Monitor, test and implement cutting edge technologies to drug new targets

    Requirements and Qualifications

    • EDUCATION
    • Ph.D. in Chemistry, Biochemistry, Enzymology or equivalent experience
    • REQUIRED EXPERIENCE
    • Ability to contribute to determining the best strategy for screening and hit characterization
    • In-depth understanding of enzymology and biochemistry with a demonstrated ability to decipher mechanism of action of small molecule modulators
    • Direct involvement with assay development for complex targets, including enzymes protein-protein interaction, allosteric modulation, ion channel and/or GPCR
    • Broad experience with implementing a variety of assay formats, such as TR-FRET, AlphaLisa, Caliper, Mass Spectrometry (RapidFire), etc.
    • Experience with developing and implementing biophysical assays for small molecule screening and small molecule characterization (e.g. ITC, SPR, NMR, DSF, etc.)
    • Experience with compound management
    • The ideal candidate will also have the following experience:
    • Working with cross functional teams in a biopharmaceutical environment
    • Outsourcing screens, assay development and implementation, as well as selectivity panels
    • Protein chemistry management for drug discovery and experience with construct design, protein expression and purification
    • Industrialization of cell assays and development / implementation of phenotypic screens
    • KNOWLEDGE SKILLS AND ABILITIES
    • Experience in a startup biotech environment
    • Relevant industry experience and working with highly collaborative matrixed project teams
    • Experience with outsourcing
    • Experience with complex targets requiring careful mechanistic evaluation, development of orthogonal assays and / or biophysical methods

  • Data Scientist, Statistical Genetics

    The Opportunity

    Goldfinch is integrating breakthroughs in kidney genetics and biology to identify new therapeutic targets and advance first-in-class drug candidates to treat patients with kidney disease. We are seeking a computational biologist, geneticist, or biostatistician who is well-versed in analyzing large sets of human genomic and transcriptomic data of complex phenotypes to work on our exciting Product Engine.

    Major Responsibilities

    • Translating human genetic discoveries in kidney disease into novel therapeutic targets.
    • Using samples obtained through collaborations and partnerships, this individual will help build a comprehensive clinical-genomics data warehouse of the highest quality. She/he will process and enforce quality control on whole genome sequences, transcriptomic (RNAseq) data, and longitudinal clinical profiles; to enable association of genetic variants with onset and progression of disease, to ultimately determine points of biological dysfunction and pathways and targets for therapeutic intervention, and association of disease state with changes in gene expression which may be useful for clinical biomarkers.
    • This individual will also collaborate with scientists to inform laboratory experiments to determine the molecular and cellular-level function of disease-associated genetic variants.
    • This is an exciting opportunity for a motivated data scientist who wishes to apply the results of genetics and genomics investigation to support the discovery of novel precision medicines.

    Requirements and Qualifications

    • EDUCATION
    • Ph.D. or M.D., in Bioinformatics, human genetics, biostatistics or related field
    • REQUIRED EXPERIENCE
    • 2-5 years’ post-degree experience in an academic or industrial setting preferred
    • Experience using large-scale phenotype and genetic data
    • Expertise in next generation sequencing statistical analysis (QC metrics, analysis of rare variation)
    • Experience using clinical data, electronic medical records, and laboratory data for analysis of complex phenotypes
    • Experience with RNAseq data analysis and eQTL studies
    • KNOWLEDGE SKILLS AND ABILITIES
    • Solid foundation in statistics and genetics
    • Knowledge of sequence alignment and variant calling pipelines (BWA, STAR, GATK, etc)
    • Knowledge of statistical genetics software (PLINK/SCAT/GAVA)
    • Experience using statistical software (R/MATLAB/SAS)
    • Programming/Scripting skills (Perl/Python/Shell/Java/Linux)
    • Deep learning algorithms a plus
    • General knowledge of Cell Biology
    • Ability to work as part of a highly collaborative team

  • Director, Information Technology & Informatics

    The Opportunity

    Goldfinch is seeking an Informatics professional to lead the design, implementation and growth of our information architecture. This individual with manage infrastructure and resources to meet organizational needs and will be responsible for working cross-functionally with all departments to identify long-term, scalable, practical solutions for research and operations as the organization grows. He/she will be expected to establish close partnerships with colleagues from multiple disciplines to translate business needs into state-of-the-art informatics solutions.

    Major Responsibilities

    • LEADERSHIP
    • Provide strong leadership and business acumen, as well as data and analytical skills and relationship-building capabilities to inspire the organization around common goals, vision and values for IT and informatics
    • Define and implement data architecture and company-wide strategy for data storage, processing, analysis and mining
    • Serve as champion for global data management, governance, quality and vendor relationships across the company
    • Establish an architecture and a collection of integrated decision-support applications and databases, providing the company easy access to corporate data
    • Grow the breadth and depth of department expertise to meet short and long-term corporate objectives
    • INFORMATION TECHNOLOGY
    • Oversee contingency planning and IT security and compliance by establishing controls and processes in support of data security, PHI, SOX and other relevant regulatory requirements
    • Manage vendors, consultants and overall budget for data management and IT
    • Lead the planning and estimation of IT &anp; Informatics projects
    • Regularly and effectively communicate with key project stakeholders, keeping them advised of project progress and generally making IT activities transparent to stakeholders
    • Set strategy for IT infrastructure and software capabilities for current and future organizational needs
    • Maintain ongoing knowledge of industry trends and ability to utilize that knowledge to determine the most efficient ways to meet business needs
    • Communicate strategy to scientific personnel, operations and senior management to ensure alignment
    • Measures availability, performance, capacity, and utilization of IT and Informatics services
    • Detects, monitors, reports, manages, escalates and ultimately prevents service failures and/or degradations
    • Take ownership of security across the board and lead IT related compliance for the Company
    • Collaborate with others to facilitate business needs definition, workflow design and integration of scientific processes and technology into effective IT solutions

    Requirements and Qualifications

    • EDUCATION
    • Advanced degree in life sciences
    • REQUIRED EXPERIENCE
    • 7-10 years of relevant experience working in Biotech
    • 5-7 years of experience managing and implementing informatics and IT solutions in a start-up, biotech environment
    • Experience with evaluating, implementing and managing scientific data management platforms, cloud computing (AWS), document control/electronic lab notebook software, on-site storage solutions and IT vendor services
    • Prior experience and record of accomplishment leading cross functional teams and delivering on schedule in a start-up biotech environment
    • Prior experience in successfully implementing, utilizing and leveraging outsourcing strategies
    • KNOWLEDGE SKILLS AND ABILITIES
    • Ability to identify impediments to complex business and research issues and provide timely and cost-effective solutions
    • Solid scientific/ technical knowledge to be able to successfully ensure project scope and fit technology for applications, networking and information systems strategic roadmap and execution of all Informatics solutions and IT services
    • Practical understanding of relational database design and development
    • Demonstrated understanding of the software development lifecycle
    • Ability to adapt to increasing scope and complexity of work brought on by growth/change and helps others manage through change
    • Strong written, oral and public speaking communication skills

  • Director of Pharmacology

    The Opportunity

    The Director of Pharmacology will develop and run in vivo assays required for the advancement of Goldfinch Bio's preclinical projects. S/he will head Goldfinch's Pharmacology function and work in close collaboration with other Goldfinch scientists to ensure that pre-clinical programs are based on solid scientific foundations and aligned to corporate goals.

    Major Responsibilities

    • Design and interpret in vivo pharmacology studies to evaluate the activities of the company's drug candidates, characterize and model PK/PD
    • Develop in vivo models to support preclinical programs and advance drug candidates to clinical development
    • Partner with Biology and Translational Medicine functions to identify and validate biomarkers for Goldfinch's therapeutic targets
    • Grow and maintain collaborative working relationship with Contract Research Organizations to execute preclinical studies
    • Grow and maintain collaborative working relationship with Contract Research Organizations to execute preclinical studies

    Requirements

    • Ph.D. or M.D.-Ph.D. in pharmacology, molecular and/or cell biology with 5+ year's relevant industry experience
    • 5+ years of experience working on early-stage and IND-enabling project teams within the pharmaceutical industry
    • Proven track record establishing and using preclinical pharmacologic and pharmacodynamic models to advance drug candidates to development
    • Hands-on experience in diverse, in vivo experimental model systems, histology and RNA/protein analysis techniques
    • Proven track record in identifying and validating biomarkers and in developing pharmacodynamic models
    • Familiarity managing outsourced pharmacodynamic and pharmacologic efficacy studies
    • Expertise in PK/PD analysis and modeling

  • Head of Translational Medicine

    The Opportunity

    The Head of Translational Medicine will be responsible for advancing the science of early development, bridging across research, preclinical and early development functions to define initial biochemical activity in first clinical indications. S/he will be responsible for designing and implementing a strategy for optimal integration of early clinical development and for defining the paths toward clinical Proof of Concept (PoC).

    Major Responsibilities

    • Provide clinical perspective as a member of cross functional teams to develop target product profiles for preclinical programs and guide IND-enabling preclinical studies to support clinical plans
    • Develop, select, and validate biomarkers to demonstrate proof of mechanism, support dose selection, and understand PK/PD relationship
    • Participate in defining portfolio strategy and guiding prioritization of novel targets
    • Partner with Goldfinch's Computational Discovery team to develop and leverage Goldfinch's patient registry to inform patient stratification and trial design
    • Develop and strengthen relationships with external stakeholders, including patient advocates, regulators, clinicians and collaborators
    • Work with senior leadership to represent the company as a translational /medical spokesperson before appropriate scientific, medical, regulatory, business and other professional meetings
    • Assist with identification and evaluation of strategic assets and collaborations to support Goldfinch's clinical development strategy
    • Collaborate with and oversee consultants and third party service providers supporting the Translational Medicine function

    Requirements and Qualifications

    • M.D. required, M.D. / Ph.D. preferred
    • 5+ years of industry experience, preferably in kidney disease and/or rare diseases
    • Strong track record in translational medicine including hands-on experience taking therapeutic programs through preclinical development into the clinic
    • Comfort and familiarity working alongside regulators to develop novel clinical paths to approval
    • Accomplished record of collaboration with internal and external multi-disciplinary research and development teams
    • Working knowledge of genetic/genomic and bioinformatics technologies and their application in translational approaches, especially in kidney disease is preferred
    • Direct experience or training in kidney disease preferred; additional experience in other therapeutic areas (e.g., cardiovascular, metabolic) is a plus

  • Senior Research Associate, Biology

    The Opportunity

    The Senior Research Associate will develop, implement and execute in vivo and in vitro assays required for the advancement of high priority projects and Goldfinch Bio's Product Engine.

    Major Responsibilities

    • Development and implementation of a diverse set of cellular assays used to support lead discovery
    • In partnership with scientific leadership design, execute, troubleshoot, and interpret biological experiments in support of program objectives
    • Interact and communicate results and conclusions to the biology team and cross-functional project teams

    Requirements and Qualifications

    • B.S. or M.S. in cell and/or molecular biology or pharmacology
    • 3 to 5 years of industry experience
    • Experience developing cellular assays used to drive early-stage programs towards candidate selection, including miniaturization and automation of high-content imaging, as well as protein and RNA assays
    • Target validation experience with ability to assay target biology with genetic perturbation techniques such as CRISPR-Cas9 and shRNA, in addition to the construction of stable cell lines expressing genes of interest
    • Demonstrated ability to thrive in a team environment
    • Strong experimental background and a rigorous, analytical approach to problem solving
    • Familiarity with high-content phenotypic screening
    • Experience with visualization software and associated analysis of rich cellular datasets
    • Some weekend work will be required

  • Senior Scientist, Biology

    The Opportunity

    The Senior Scientist will play an integral role as a member of Goldfinch's Biology team, focusing on advancing the Company's product engine to identify and validate novel targets to treat kidney disease.

    Major Responsibilities

    • Independently design, execute, troubleshoot, and interpret biological experiments in support of target identification, validation, and lead discovery
    • Prepare SOPs for diverse assays and maintain accurate documentation of experiments
    • Engage and interact with the biology group, cross-functional project teams, and to senior management to discuss experimental results and conclusions

    Requirements and Qualifications

    • Ph.D. in cell and/or molecular biology
    • 3 to 5+ years of relevant industry experience
    • Hands-on, independent experience in diverse in vitro experimental model systems including CRISPR-Cas9, shRNA, and protein expression techniques
    • Proven track record developing cell assays to support optimization of molecules and/or phenotypic screening using high content microscopy or other imaging systems
    • Detailed familiarity with cytoskeletal and/or cell death biology
    • Experience with iPSC/ESC and organoid biology
    • Experience leading drug discovery projects

  • Senior Scientist, Medicinal Chemistry

    The Opportunity

    The Senior Scientist, Medicinal Chemistry will be working with our internal and external medicinal chemistry groups to design and synthesize small molecules in the pursuit of target validation, hit-to-lead and lead optimization. The successful candidate will engage in synthetic and medicinal chemistry problem solving and will collaborate across disciplines to advance Goldfinch's therapeutic programs.

    Major Responsibilities

    • Work with Goldfinch Bio's internal and external medicinal chemistry groups to successfully advance programs
    • Analyze data and collaborate with multidisciplinary teams to prioritize synthetic targets
    • Lead and oversee effective interactions with CROs
    • Lead medicinal and synthetic chemistry efforts, demonstrate high level of problem solving and creativity Interpret and communicate results within Medicinal Chemistry team and across multifunctional project teams

    Requirements and Qualifications

    • Ph.D. in synthetic organic chemistry
    • 5+ years of industry experience
    • Strong track record in impacting hit-to-lead and lead optimization programs
    • High level of creativity and productivity with strong synthetic chemistry problem solving skills
    • Proven ability to work collaborate effectively with others in a dynamic and highly matrixed environment
    • Experience working with CROs is preferred

Note to Recruitment Agencies: Please do not forward any agency resumes. Goldfinch Bio is not responsible for any fees related to resumes that are unsolicited.
 
Equal Opportunity Employer M/F/D/V.